Summary

Eligibility
for people ages 18-99 (full criteria)
Location
at San Diego, California and other locations
Dates
study started
completion around
Principal Investigator
by Bethany Karl, DO

Description

Summary

Official Title

A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Keywords

Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, Nephritis, Lupus Nephritis, Systemic Lupus Erythematosus, Cyclophosphamide, Rituximab, Fludarabine, Obinutuzumab

Eligibility

Locations

  • University of California, San Diego accepting new patients
    San Diego California 92121 United States
  • University of Alabama at Birmingham (UAB) accepting new patients
    Birmingham Alabama 35294 United States

Lead Scientist at UCSD

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Artiva Biotherapeutics, Inc.
ID
NCT06265220
Phase
Phase 1 Lupus Research Study
Study Type
Interventional
Participants
Expecting 51 study participants
Last Updated